Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests

This publication has 14 references indexed in Scilit:

• Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.
  Environmental Health Perspectives, 1998
• Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells
  British Journal of Cancer, 1997
• Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro
  Cancer Chemotherapy and Pharmacology, 1997
• Myelotoxic effects of the bifunctional alkylating agent bizelesin on human, canine and murine myeloid progenitor cells
  Cancer Chemotherapy and Pharmacology, 1996
• The Use of In Vitro Systems for Evaluating Haematotoxicity
  Alternatives to Laboratory Animals, 1996
• Human haemopoietic stem cell assays
  Blood Reviews, 1993
• Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning
  Toxicologic Pathology, 1993
• Comparativein vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells
  Investigational New Drugs, 1992
• In vitro toxicity of 3′‐azido‐3′‐deoxythymidine, carbovir and 2′, 3′‐didehydro‐2′, 3′‐dideoxythymidine to human and murine haematopoietic progenitor cells
  British Journal of Haematology, 1992
• Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development
  JNCI Journal of the National Cancer Institute, 1990